RxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call Transcript

And we hope to introduce that in the second half of 2023. Now that subject, one, to FDA approval, but just as importantly to supply chain. That continues to be difficult, although we work very closely to bring those components in, as well as the components that we’re bringing in through our current product. And that’s the strategy to improve the margin on the LDD side as we grow in the second half of next year. And I think just the important thing to remind ourselves again is that, it’s the same functionality, but it was designed over a several year period to take out some of the cost. And so, that’s an important initiative for us in terms of increasing margin, but just as importantly continuing to grow our LAL procedure volume. That is what really drives margin.

Ryan Zimmerman: Very helpful, Shelley. Thank you, and congrats again. Very exciting to see.

Shelley Thunen: Thank you very much.

Operator: Thank you. And at this time, I would like to turn it back to Dr. Kurtz for our closing remarks.

Ron Kurtz: Great. Well, thank you all for your time and attention today and for your continued interest in RxSight. Wish the best for the rest of the day. Thank you.

Operator: This concludes our program for the day. Thank you very much for your participation. Have a wonderful day.